The Schall Law Firm is organizing a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased the company's securities during a specific window in late 2025. The lawsuit alleges that the biopharmaceutical company made materially false and misleading statements regarding FDA approval prospects for its Pivotal Study and mischaracterized the risk of delays to its Biologics License Application (BLA) timeline.
According to the litigation notice, eligible investors are those who purchased uniQure securities between September 24, 2025, and October 31, 2025, and experienced financial losses as a result of the alleged misrepresentations. The class action mechanism allows multiple affected shareholders to consolidate their claims into a single proceeding against the company.
Investors seeking to participate in the lawsuit or be appointed as lead plaintiff must contact the Schall Law Firm before the April 13, 2026 deadline. The firm specializes in securities litigation and represents shareholders alleging violations of federal securities laws.